We are excited to welcome the talented team at Regulus to Novartis as we continue to build on our pipeline in renal disease with high unmet medical need.” Farabursen is an investigational ...

Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Novartis works closely with healthcare professionals around the world to support ...

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the ...

Career Search. Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.. Notice to applicants for US job ...

Careers at Novartis in Slovenia. At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to ...

For the estimated 2.8 million people 1 living with multiple sclerosis (MS) worldwide, diagnosis is life-altering and can be overwhelming. The symptoms, including loss of vision, movement and sensation ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

The purpose of this study is to evaluate the efficacy, safety and tolerability of QCZ484 or placebo, given subcutaneously, every 6 months, at different dose levels in patients with mild to moderate ...

In today's rapidly evolving healthcare landscape, there is a profound shift in how patients approach their cancer diagnosis and treatment. Novartis has been committed to extending and improving lives ...

NATALEE subanalysis evaluates Kisqali in pre-menopausal early breast cancer patients, amid rising diagnosis rates in younger patients Pluvicto analysis and Scemblix ASC4START primary endpoint results ...

Serving the Emerging Needs of Today's Cancer Patients . As Bultó shared on the panel, there has been a 79% increase in the global incidence of early onset cancer 1.At the same time, people 85 years ...

Syftet med studien är att utvärdera effekt och säkerhet av remibrutinib (LOU064) när det ges till patienter med skovvis förlöpande multipel skleros. Studiens huvudsyfte är att ta reda på om patienter ...